Expression of p21(WAF1/Cip1) in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2445-2449

  Natsugoe, Shoji ^a   Nakashima, Saburo ^a   Matsumoto, Masataka ^a   Xiangming, Che ^a   Okumura, Hiroshi ^a   Kijima, Fumio ^a   Ishigami, Sumiya ^a   Takebayashi, Yuji ^a   Baba, Masamichi ^a   Takao, Sonshin ^a   Aikou, Takashi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL CYCLE; ESOPHAGUS CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; BIOSYNTHESIS; ESOPHAGUS TUMOR; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032588893     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. McBride, W., Merry, D., and Givol, D. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc. Natl. Acad. Sci. USA, 83: 130-134, 1986.
2. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
3. Imazeki, F., Omata, M., Nose, H., Ohto, M., and Isono, K. p53 gene mutations in gastric and esophageal cancers. Gastroenterology, 103: 892-896, 1992.
4. Hollstein, C., Metcalf, R. A., Welsh, J. A., Montesano, R., and Harris, C. C. Frequent mutation of the p53 gene in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 87: 9958-9961, 1990.
5. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 cdk-interacting protein Cip1 is a potent inhibitor of C1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
6. Xiong, Y., Hannon, GJ., Zang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
7. Komiya, T., Hosono, Y., Hirashima, T., Masuda, N., Yasumitsu, T., Nakagawa, K., Kikui, M., Ohno, A., Fukuoka, M., and Kawase, I. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin. Cancer Res., 3: 1831-1835, 1997.
8. waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int. J. Cancer, 74: 529-534, 1997.
9. Gomyo, Y., Ikeda, M., Osaki, M., Tatebe, S., Tsujitani, S., Ikeguchi, M., Kaibara, N., and Ito, H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in survival of patients with advanced gastric carcinoma. Cancer (Phila.), 79: 2067-2072, 1997.
10. Ikeguchi, M., Saito, H., Katano, K., Tsujitani, S., Maeta, M., and Kaibara, N. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Digest. Dis. Sci., 43: 964-970, 1998.
11. El-Deiry, S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Marcer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
12. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. D., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
13. Coggi, G., Bosari, S., Roncalli, M., Graziani, D., Bossi, P., Viale, G., Buffa, R., Ferrero, S., Piazza, M., Blandamura, S., Segalin, A., Bonavina, L., and Peracchia, A. p53 protein accumulation and p53 gene mutation in esophageal carcinoma: a molecular and immunohistochemical study with clinicopathologic correlations. Cancer (Phila.), 79: 425-432, 1997.
14. Casson, A. G., Tammemagi, M., Eskandarian, S., Redston, M., McLaughlin, J., and Ozcelik, H. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol. Pathol., 51: 71-79, 1998.
15. Sobin, L. H., and Wittwkind, C. H. (eds.). TNM Classification of Malignant Tumors. International Union Against Cancer, Ed. 5. New York: John Wiley & Sons, 1997.
16. Finaly, C. A., Hinds, P. W., Tan, T. H., Eliyabu, D., Oren, M., and Levine, A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol., 8: 531-539, 1988.
17. Shiohara, M., EL-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutation in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
18. Ikeguchi, M., Saito, K., Katano, Y., Gomyo, Y., Tsujitani, S., Maeta, M., and Kaibara, N. Relationship between the long-term effects of intraperitoneal chemotherapy and the expression of p53 and p21 in patients with gastric carcinoma at Stage IIIa and IIIb. Int. Surg., 82: 170-174, 1997.
19. Missero, C., Calautti, E., Eckner, G., Chin, J., Tsai, L., Livingston, D. M., and Dotto, G. P. Involvement of the cell-cycle inhibitor Cip1/ Waf1 and E1A-associated p300 protein in terminal differentiation. Proc. Natl. Acad. Sci. USA, 92: 5451-5455, 1995.
20. Ebinuma, H., Saito, H., Tada, S., Kurose, I., Kaneko, F., Takahashi, M., Ohishi, T., Watanabe, T., and Ishii, H. The role of the cyclin-dependent-kinase inhibitor p21 Waf1 in the maintenance of differentiating hepatoma cells. Gastroenterology, 112 (Suppl.), A1259, 1997.
21. Shimaya, K., Shiozaki, H., Inoue, M., Tahara, H., Monden, T., Shimano, T., and Mon, T. Significance of p53 expression as a prognostic factor in esophageal squamous cell carcinoma. Virchow Arch. A Pathol. Anat. Histopathol., 422: 271-276, 1993.
22. Monges, G. M., Seitz, J. F., Giovannini, M. F., Gouvernet, J. M., Torrente, M. A., and Hassoun, J. A. Prognostic value of p53 protein expression in squamous cell carcinoma of the esophagus. Cancer Detect. Prev., 20: 63-67, 1996.
23. Sarbia, M., Porschen, R., Borchard, F., Horstmann, O., Willers, R., and Gabbert, H. E. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer (Phila.), 15: 2218-2223, 1994.
24. Vijeyasingam, R., Darnton, S. J., Jenner, K., Allen, C. A., Billingham, C., and Matthews, H. R. Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br. J. Surg., 81: 1623-1626, 1994.
25. WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities. Clin. Cancer Res., 4: 2615-2623, 1998.
26. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., and Wang, X. F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA, 92: 5545-5549, 1995.
27. WAF1/CiP1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J. Pathol., 184: 265-271, 1998.
28. Bukholm, I. K., Nesland, J. M., Karesen, R., Jacobsen, U., and Borresen-Dale, A. L. Interaction between bc1-2 and p21 (WAF1/CIP1) in breast carcinoma with wild-type p53. Int. J. Cancer, 73: 38-41, 1997.
29. WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int. J. Cancer, 55: 2404-2409, 1995.
30. Roder, J. D., Busch, R., Stein, H. J., Fink, U., and Siewert, J. R. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the esophagus. Br. J. Surg., 81: 41-43, 1994.
31. Baba, M., Aikou, T., Yoshinaka, H., Natsugoe, S., Fukumoto, T., Shimazu, H., and Akazawa, K. Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann. Surg., 219: 310-316, 1994.